Neurofibromatosis Type 1

What NF1 is

NF1 is caused by a disease-causing change in the NF1 gene. The gene helps regulate cell growth. The condition can cause pigment changes and benign tumors called neurofibromas, along with a range of eye, bone, vascular, neurologic, developmental, and cancer-related concerns.

Expression is highly variable. Two people in the same family can have different features and severity. A child’s future cannot be predicted simply from a parent’s experience, the number of café-au-lait spots, or one genetic result.

NF1 is not contagious and is not caused by parenting, food, stress, or something a person did during pregnancy. Older names can carry stigma and are not needed for respectful care.

Possible features across life

Café-au-lait macules are flat areas darker than surrounding skin. Freckling in the armpits or groin can develop. These findings can be easier or harder to recognize depending on skin tone and lighting. A small number of pigment spots is common in the general population and does not diagnose NF1.

Cutaneous neurofibromas are benign growths on or just under skin and become more common with age. Plexiform neurofibromas grow along larger nerves and can involve deeper tissues. Their effect depends on location and size. A lump cannot be classified by appearance alone.

Some children have learning, attention, language, motor, or behavioral difficulties. Most people do not have global intellectual disability. Support should be based on an individual assessment rather than lowered expectations.

Bone changes, scoliosis, high blood pressure, headaches, seizures, pain, sleep problems, or vision concerns can occur. Optic pathway gliomas are more frequent in NF1, but many do not cause symptoms or require treatment. Routine monitoring focuses on function and clinical signs.

Changes that need prompt assessment

Seek prompt specialist review for a rapidly enlarging or newly hard mass, persistent or severe pain, pain that wakes a person, new weakness or numbness, change in walking, or loss of function. These findings have several possible causes but can signal a problem within a plexiform neurofibroma.

New vision loss, an abnormal eye movement, new persistent headache with neurologic changes, seizure, or early puberty signs in a child needs timely assessment. Sudden severe headache, stroke warning signs, breathing difficulty, collapse, or another immediate emergency requires emergency services.

High blood pressure may be related to common causes or less common NF1-associated vascular or adrenal problems. Severe blood pressure with chest pain, neurologic symptoms, shortness of breath, or confusion is an emergency. Do not attempt to diagnose the cause with a home cuff.

How diagnosis is established

Clinicians use internationally accepted diagnostic criteria that combine features such as pigment findings, freckling, neurofibromas, certain eye findings, specific bone lesions, an affected parent, or a pathogenic NF1 variant. A person generally needs a qualifying combination, not one isolated sign.

Features appear at different ages, so a young child may not yet meet criteria even when NF1 is suspected. Follow-up can be more informative than repeated unsupervised testing. Other conditions, including Legius syndrome and mosaic NF1, can produce overlapping pigment patterns and need different interpretation.

Genetic testing can confirm many cases, help distinguish look-alikes, and support family planning. A negative test does not exclude every clinical case because methods and variant types have limits. A variant of uncertain significance is not proof and should not guide irreversible decisions.

Testing a tumor alone is different from identifying a germline change present throughout the body. Results should be interpreted by a genetics professional who can explain laboratory classification, mosaicism, family testing, and reproductive options.

Inheritance and family questions

NF1 follows an autosomal dominant inheritance pattern. An affected person has a chance of passing the altered gene in each pregnancy, but the severity in a child cannot be predicted. About half of affected people have a new change rather than inheriting it from a parent.

Parents who do not meet criteria can still need assessment when a child has NF1, particularly when mosaicism is considered. Siblings and other relatives should not be labeled from photographs. Genetic counseling can clarify who may benefit from evaluation or testing.

Reproductive options are personal. Preconception, prenatal, and embryo testing have technical and ethical limits, including inability to predict severity. Counseling should support informed choice without pressure.

Age-appropriate surveillance

Children usually need regular review of growth, blood pressure, skin, vision, development, school progress, bones, pain, and neurologic symptoms. Eye assessment is particularly important in childhood. Routine brain or whole-body imaging is not automatically recommended for every person without symptoms.

Adults continue blood-pressure, neurologic, skin, pain, bone, mental health, and tumor assessment. Breast-cancer screening recommendations can differ for women with NF1, especially at younger adult ages. The exact schedule depends on current guidelines and local resources.

Surveillance is intended to find actionable problems while avoiding unnecessary radiation, sedation, false alarms, and incidental findings. A specialist familiar with NF1 can adapt the plan to known tumors, symptoms, prior treatment, and family history.

Treatment and symptom support

There is no single treatment for all NF1 features. A neurofibroma may be observed, surgically removed, or treated in another way based on pain, function, growth, appearance, location, and cancer concern. Surgery can be complex when a tumor involves major nerves or vessels.

Targeted medicines are available for selected people with symptomatic, inoperable plexiform neurofibromas. Eligibility, expected benefit, adverse effects, monitoring, age, and access require an experienced team. This page does not determine who should receive a specific drug.

Learning, attention, speech, motor, pain, sleep, hearing, vision, and mental health needs can be treated or supported even when no tumor treatment is needed. School services, occupational or physical therapy, psychology, pain care, and social support can improve daily function.

Cosmetic and visible differences can lead to bullying or discrimination. Care should respect whether a person wants treatment, concealment, disclosure, or support. A benign lesion is not medically trivial when it causes pain, itching, trauma, or major psychosocial burden.

Pregnancy and other life transitions

Pregnancy can change neurofibroma symptoms or size for some people and requires blood-pressure and obstetric planning. Anesthesia, spinal tumors, vascular problems, and prior surgeries may matter. Preconception discussion with NF and obstetric teams can organize safe care without assuming pregnancy is impossible.

Transition from pediatric to adult care should include a current problem list, known tumors, imaging, genetics report, surgeries, medicines, blood-pressure history, learning support, and clear surveillance plan. Losing follow-up during this transition can delay recognition of treatable problems.

Preparing for an NF clinic visit

Bring genetic and pathology reports, prior imaging, growth or vision records, school evaluations, blood-pressure readings, and a list of new or changing symptoms. Photographing a visible lesion over time with consistent scale can help, but images do not replace examination.

Ask which findings establish the diagnosis, which changes need urgent contact, what screening applies at the person’s age, and which specialist coordinates care. Clarify whether imaging is for a symptom, known tumor, or surveillance and what result would change treatment.

Common questions

Does every café-au-lait spot mean NF1?

No. One or a few spots are common. Number, size, age, distribution, other features, and family history matter. Similar pigment patterns occur in other genetic conditions. A clinician should apply the complete criteria rather than diagnose from a photo.

Are all neurofibromas cancer?

No. Most neurofibromas are benign. NF1 does raise the risk of particular cancers, and a rapidly changing, hard, persistently painful, or function-limiting mass needs prompt assessment. Fear of cancer should not lead to unnecessary removal of every stable lesion.

Should every person have routine whole-body MRI?

Not automatically. Imaging is selected from age, symptoms, known plexiform tumors, examination, prior findings, and what a result would change. More scanning can also produce incidental findings, anxiety, sedation exposure, and procedures that do not help.

Can a parent predict a child’s severity?

No. NF1 varies widely, even within a family carrying the same variant. Genetics can clarify inheritance but usually cannot forecast the exact number of tumors, learning profile, complications, or treatment needs.

Is appearance-focused care legitimate?

Yes. Visible neurofibromas and pigment changes can affect comfort, clothing, work, relationships, and mental health. Discussing appearance is not vanity. The person’s goals should guide whether observation, removal, concealment, counseling, or support is appropriate.

Before a procedure, ask about scarring, recurrence, nerve injury, healing, cost, and whether pathology testing is recommended.

Specialist experience matters because lesion depth and nearby nerves can change procedural risk.